

Jonathan N Townend

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5210852/jonathan-n-townend-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76
papers

2,767
citations

27
h-index

52
g-index

90
ext. papers

3,333
ext. citations

5.2
avg, IF

4.77
L-index

#	Paper	IF	Citations
76	Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 514-25	18.1	381
75	Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 505-12	15.1	214
74	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. <i>BMJ, The</i> , 2015 , 351, h4451	5.9	172
73	Nitric oxide and cardiac autonomic control in humans. <i>Hypertension</i> , 2000 , 36, 264-9	8.5	136
72	Role of nitric oxide in the regulation of cardiovascular autonomic control. <i>Clinical Science</i> , 1999 , 97, 5-17	6.5	105
71	Arterial stiffness in chronic kidney disease: causes and consequences. <i>Heart</i> , 2010 , 96, 817-23	5.1	104
70	Arterial disease in chronic kidney disease. <i>Heart</i> , 2013 , 99, 365-72	5.1	97
69	The haemodynamic effects of adjunctive hormone therapy in potential heart donors: a prospective randomized double-blind factorially designed controlled trial. <i>European Heart Journal</i> , 2009 , 30, 1771-80	9.5	95
68	Cardiovascular effects of sevelamer in stage 3 CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013 , 24, 842-52	12.7	90
67	Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association?. <i>Atherosclerosis</i> , 2012 , 223, 86-94	3.1	88
66	Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. <i>BMC Nephrology</i> , 2016 , 17, 127	2.7	83
65	Mechanical effects of left ventricular midwall fibrosis in non-ischemic cardiomyopathy. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016 , 18, 1	6.9	82
64	Comparison of magnetic resonance feature tracking for systolic and diastolic strain and strain rate calculation with spatial modulation of magnetization imaging analysis. <i>Journal of Magnetic Resonance Imaging</i> , 2015 , 41, 1000-12	5.6	78
63	Diffuse interstitial fibrosis and myocardial dysfunction in early chronic kidney disease. <i>American Journal of Cardiology</i> , 2015 , 115, 1311-7	3	69
62	Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance. <i>JACC: Cardiovascular Imaging</i> , 2014 , 7, 703-14	8.4	68
61	Quantification of left ventricular interstitial fibrosis in asymptomatic chronic primary degenerative mitral regurgitation. <i>Circulation: Cardiovascular Imaging</i> , 2014 , 7, 946-53	3.9	67
60	Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors. <i>Hypertension</i> , 2016 , 67, 368-78	5.5	66

59	Transcatheter Aortic Valve Implantation With or Without Percutaneous Coronary Artery Revascularization Strategy: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	62
58	Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. <i>American Journal of Kidney Diseases</i> , 2013 , 62, 615-32	7.4	57
57	Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. <i>Heart</i> , 2012 , 98, 219-24	5.1	55
56	Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 2576-82	4.3	51
55	Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. <i>American Journal of Cardiology</i> , 2010 , 106, 1505-11	3	47
54	The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 447-54	3.8	43
53	Echocardiography in the potential heart donor. <i>Transplantation</i> , 2010 , 89, 894-901	1.8	39
52	Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 2497-2508	27.4	35
51	Coronary Artery Calcium Assessment in CKD: Utility in Cardiovascular Disease Risk Assessment and Treatment?. <i>American Journal of Kidney Diseases</i> , 2015 , 65, 937-48	7.4	31
50	A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. <i>BMJ Open</i> , 2017 , 7, e015099	3	29
49	Cytomegalovirus seropositivity is associated with increased arterial stiffness in patients with chronic kidney disease. <i>PLoS ONE</i> , 2013 , 8, e55686	3.7	26
48	Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 257 mg once daily with a diuretic combination of furosemide 40 mg daily and hydrochlorothiazide 25 mg versus	2.8	22
47	Early effects of kidney transplantation on the heart - A cardiac magnetic resonance 160 multi-parametric study. <i>International Journal of Cardiology</i> , 2019 , 293, 272-277	3.2	15
46	Prognostic Utility of Calcium Scoring as an Adjunct to Stress Myocardial Perfusion Scintigraphy in End-Stage Renal Disease. <i>American Journal of Cardiology</i> , 2016 , 117, 1387-96	3	15
45	Effect of A Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central hemodynamics: rationale and design of the EARNEST study. <i>American Heart Journal</i> , 2014 , 167, 141-149.e2	4.9	15
44	Coronary microvascular dysfunction: a key step in the development of uraemic cardiomyopathy?. <i>Heart</i> , 2019 , 105, 1302-1309	5.1	14
43	Effects of age and chronic kidney disease on regional aortic distensibility: a cardiovascular magnetic resonance study. <i>International Journal of Cardiology</i> , 2013 , 168, 4249-54	3.2	14
42	Republished paper: Arterial stiffness in chronic kidney disease: causes and consequences. <i>Postgraduate Medical Journal</i> , 2010 , 86, 560-6	2	14

41	The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. <i>Clinical Endocrinology</i> , 2010 , 73, 566-72	3.4	13
40	Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015 , 16, 599-613	3	12
39	Does immunosuppressant medication lower blood pressure and arterial stiffness in patients with chronic kidney disease? An observational study. <i>Hypertension Research</i> , 2011 , 34, 113-9	4.7	12
38	Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial. <i>BMJ Open</i> , 2016 , 6, e010519	3	12
37	Clinical Potential of Targeting Fibroblast Growth Factor-23 and Klotho in the Treatment of Uremic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2020 , 9, e016041	6	11
36	Endothelial nitric oxide synthase single nucleotide polymorphism and left ventricular function in early chronic kidney disease. <i>PLoS ONE</i> , 2015 , 10, e0116160	3.7	11
35	A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial. <i>American Heart Journal</i> , 2017 , 191, 37-46	4.9	10
34	Aortic calcification and femoral bone density are independently associated with left ventricular mass in patients with chronic kidney disease. <i>PLoS ONE</i> , 2012 , 7, e39241	3.7	10
33	Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial. <i>Trials</i> , 2011 , 12, 30	2.8	10
32	Defining Myocardial Abnormalities Across the Stages of Chronic Kidney Disease: A Cardiac Magnetic Resonance Imaging Study. <i>JACC: Cardiovascular Imaging</i> , 2020 , 13, 2357-2367	8.4	9
31	Chronic kidney disease as a cardiovascular risk factor: lessons from kidney donors. <i>Journal of the American Society of Hypertension</i> , 2018 , 12, 497-505.e4		8
30	Caveolin-1 single-nucleotide polymorphism and arterial stiffness in non-dialysis chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1140-4	4.3	7
29	Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial. <i>Trials</i> , 2014 , 15, 158	2.8	6
28	Phosphate: are we squandering a scarce commodity?. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 163-83	4.3	5
27	Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors at 5 Years. <i>Hypertension</i> , 2021 , 77, 1273-1284	8.5	5
26	Arterial stiffness in chronic kidney disease: a modifiable cardiovascular risk factor?. <i>Current Opinion in Nephrology and Hypertension</i> , 2019 , 28, 527-536	3.5	5
25	Changes in Blood Pressure and Arterial Hemodynamics following Living Kidney Donation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 1330-1339	6.9	4
24	Myocardial characterization in pre-dialysis chronic kidney disease: a study of prevalence, patterns and outcomes. <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 295	2.3	4

23	Comparison of Routine Versus Selective Glycoprotein IIb/IIIa Inhibitors Usage in Primary Percutaneous Coronary Intervention (from the British Cardiovascular Interventional Society). <i>American Journal of Cardiology</i> , 2019 , 124, 373-380	3	3
22	Coronary flow velocity reserve and inflammatory markers in living kidney donors. <i>International Journal of Cardiology</i> , 2020 , 320, 141-147	3.2	3
21	Impaired circumferential and longitudinal myocardial deformation in early stage chronic kidney disease: the earliest features of uremic cardiomyopathy. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2013 , 15,	6.9	3
20	Changes in left ventricular structure and function associated with renal transplantation: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2021 , 8, 2045-2057	3.7	3
19	Improving the diagnosis of heart failure in patients with atrial fibrillation. <i>Heart</i> , 2021 , 107, 902-908	5.1	3
18	What is the cause of hypotension? A rare complication of percutaneous coronary intervention of a chronic total occlusion: a case report. <i>European Heart Journal - Case Reports</i> , 2019 , 3, 1-5	0.9	2
17	Sudden cardiac death in chronic renal disease: aetiology and risk reduction strategies. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 1386-1388	4.3	2
16	Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 1491-1501	6.9	2
15	10 Cardiac alterations after renal transplant; controversies unravelled by cardiac mri. <i>Heart</i> , 2017 , 103, A6-A7	5.1	1
14	Upregulation of the nitric oxide-cGMP pathway in aged myocardium. <i>Circulation Research</i> , 2001 , 88, E48	15.7	1
13	The characteristics of mitral regurgitation: Data from patients admitted following acute myocardial infarction. <i>Data in Brief</i> , 2021 , 39, 107451	1.2	1
12	CKD Associated Cardiomyopathy: Molecular Mechanisms, Imaging Modalities, Disease Evolution and Interventions 2017 , 45-58		1
11	Acute Presentation of Structural Valve Degeneration in a Transcatheter Heart Valve (Sapien XT) at 7.5 Years; Successful Redo TAVR With a Sapien 3 Ultra. <i>CJC Open</i> , 2021 , 3, 383-386	2	1
10	Mitral Regurgitation Following Acute Myocardial Infarction Treated by Percutaneous Coronary Intervention-Prevalence, Risk factors, and Predictors of Outcome. <i>American Journal of Cardiology</i> , 2021 , 157, 22-32	3	1
9	Risk for subsequent hypertension and cardiovascular disease after living kidney donation: is it clinically relevant?. <i>CKJ: Clinical Kidney Journal</i> , 2022 , 15, 644-656	4.5	1
8	Results of Serial Myocardial Perfusion Imaging in End-Stage Renal Disease. <i>American Journal of Cardiology</i> , 2018 , 121, 661-667	3	0
7	MP387CARDIAC LIMITATION OCCURS EARLY IN CKD, AND CANNOT BE FULLY EXPLAINED BY ISCHAEMIA OR REDUCED LV COMPLIANCE AS MEASURED BY DIASTOLIC FUNCTION DURING EXERCISE. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, iii570-iii570	4.3	
6	MP392CARDIOPULMONARY EXERCISE TESTING DETECTS SUBCLINICAL CARDIAC LIMITATION TO EXERCISE IN EARLY STAGE CKD. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, iii572-iii572	4.3	

- 5 The EARNEST study: interarm blood pressure differences should also be recorded. *American Heart Journal*, **2014**, 168, e9 4.9
- 4 11 Cpx testing detects subclinical cardiac limitation to exercise in early stage ckd. *Heart*, **2017**, 103, A7.1-A7 5.1
- 3 37 Cardiovascular Effects of Unilateral Nephrectomy in Human Kidney Donors. *Heart*, **2015**, 101, A20.2-A21 5.1
- 2 Letter by Moody et al regarding article "Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction". *Circulation*, **2012**, 126, e62; author reply e64-5 16.7
- 1 Screening for occult coronary artery disease in potential kidney transplant recipients: time for reappraisal?. *CKJ: Clinical Kidney Journal*, **2021**, 14, 2472-2482 4.5